Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Starch × Gastrointestinal × Clear all

Phase

Status

Sponsor Class

OTHER 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1 Gastrointestinal 1

Conditions

Gastrointestinal Toxicity 1

Interventions

Gemcitabine 297 Fluorouracil 289 Bevacizumab 266 Oxaliplatin 264 Capecitabine 229 Leucovorin 224 pembrolizumab 215 Irinotecan 180 Cisplatin 141 Cetuximab 140 Nivolumab 129 Paclitaxel 114 130-nm albumin-bound paclitaxel 114 Sorafenib 86 Albumin-Bound Paclitaxel 74 regorafenib 64 atezolizumab 64 Docetaxel 64 IFL protocol 61 Folfox protocol 60 Trastuzumab 54 durvalumab 46 Panitumumab 46 Ramucirumab 43 Sunitinib 41 Injections 41 Drug Therapy 41 Carboplatin 40 trifluridine tipiracil drug combination 38 lenvatinib 37

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02351089 2020-03-05

ProRad

Probi AB

Phase NA Terminated

GastrointestinalGynecologic

Gastrointestinal Toxicity

Data powered by HemOnc (CC BY 4.0) Colophon ⚡